ValuEngine lowered shares of Danaher (NYSE:DHR) from a buy rating to a hold rating in a research note issued to investors on Thursday morning.
DHR has been the topic of several other reports. Robert W. Baird reiterated a buy rating and issued a $106.00 target price on shares of Danaher in a report on Friday, April 20th. Jefferies Financial Group reiterated a buy rating and issued a $117.00 target price on shares of Danaher in a report on Friday, April 20th. Credit Suisse Group reiterated an outperform rating on shares of Danaher in a report on Friday, March 9th. Stifel Nicolaus reiterated a buy rating and issued a $114.00 target price (up from $108.00) on shares of Danaher in a report on Thursday, April 19th. Finally, Morgan Stanley increased their target price on shares of Danaher from $112.00 to $113.00 and gave the stock an overweight rating in a report on Friday, April 20th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company. Danaher currently has an average rating of Buy and a consensus price target of $105.69.
DHR opened at $99.30 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.15 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $68.40 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 1.84 and a beta of 1.03. Danaher has a twelve month low of $78.97 and a twelve month high of $104.82.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 27th. Investors of record on Friday, June 29th will be issued a dividend of $0.16 per share. The ex-dividend date is Thursday, June 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.64%. Danaher’s payout ratio is 15.88%.
In related news, Director Linda P. Hefner sold 18,001 shares of the firm’s stock in a transaction on Thursday, April 26th. The shares were sold at an average price of $101.51, for a total transaction of $1,827,281.51. Following the sale, the director now directly owns 25,225 shares in the company, valued at $2,560,589.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Daniel L. Comas sold 25,206 shares of Danaher stock in a transaction on Friday, April 20th. The shares were sold at an average price of $101.39, for a total transaction of $2,555,636.34. Following the completion of the sale, the chief financial officer now owns 148,769 shares in the company, valued at $15,083,688.91. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 241,940 shares of company stock worth $24,527,925. 11.90% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. CNB Bank acquired a new stake in Danaher in the 4th quarter valued at $116,000. Truewealth LLC acquired a new stake in Danaher in the 4th quarter valued at $121,000. Zions Bancorporation acquired a new stake in Danaher in the 1st quarter valued at $123,000. Institutional & Family Asset Management LLC acquired a new stake in Danaher in the 1st quarter valued at $171,000. Finally, Private Capital Group LLC increased its stake in Danaher by 445.0% in the 1st quarter. Private Capital Group LLC now owns 1,744 shares of the conglomerate’s stock valued at $171,000 after buying an additional 1,424 shares during the last quarter. Hedge funds and other institutional investors own 76.55% of the company’s stock.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.